At December 31, 2022, the company had available cash reserves and short-term investments of $163.1M. The company’s cash position is expected to be sufficient to fund current and planned operations through 2025. "Building on our momentum and encouraging clinical results observed in 2022, we continue to advance our studies of EPI-7386, ESSA’s first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer," stated CEO David Parkinson. "In the first half of 2023, we expect to complete the Phase 1 EPI-7386 combination study with Xtandi in patients with mCRPC naive to second generation anti-androgens and to initiate the Phase 2 randomized study in the same patient population shortly thereafter. In addition, our cash runway continues to be strong and is expected to fund our operations and clinical programs through 2025."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EPIX:
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022
- Director of Essa Pharma Berger sells $729K in company shares
- Essa Pharma price target lowered to $17 from $23 at Oppenheimer
- ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022
- Essa Pharma reports Q4 EPS (14c), consensus (27c)
